2,264 press releases in English indexed under biotech & pharma.
Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new and existing investors
New York, New York--(October 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
Robbins LLP is investigating whether UNCY failed to properly inspect its third-party vendor's manufacturing facility per FDA requirements.
Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpoint Consistent with prior studies, VQW-765 was safe and well tolerated WASHINGTON, Oct. 14, 2026 -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an...
New AI platform GenoMorph identifies candidate regulatory DNA linked to the dodo's distinctive craniofacial anatomy, while technologies adapted from earlier species programs advance Nicobar pigeon germ-cell development, chicken stem-cell chimeras and embryo gene editing. DALLAS, Oct. 14,...
Multi-site Program Demonstrates Threefold Increase in Rehabilitation Training Dose, With 84% Delivered Independently and Significant Improvements Across Functional Measures GENEVA, SWITZERLAND - October 14, 2026 - MindMaze Therapeutics (SIX: MMTX), a global leader in scalable precision neurotherapeutics, today announced new real-world evidence from a multi-site program conducted with Vibra Healthcare, presented yesterday at the American Congress of Rehabilitation Medicine (ACRM) in Washington, DC. The program demonstrated that home-based rehabilitation using MindMotion increased total motor-training dose by a median factor of three compared with usual outpatient therapy alone. 84% of active training was completed independently, without direct therapist supervision. Participants also showed statistically significant improvements in functional independence, balance, mobility and cognition, alongside high patient satisfaction. Building on previously reported inpatient results with Vibra Healthcare, the findings further support MindMaze Therapeutics' strategy to extend high-dose, high-intensity neurorehabilitation into patients' homes. This is particularly relevant to the Company's upcoming launch of MindMotion Lite, expected by year-end 2026. Recently announced, the tablet-based solution is designed to deliver the full range of MindMotion GO neurotherapeutic activities with substantially reduced hardware requirements, simplifying home deployment and supporting broader adoption by healthcare providers. “Earlier this year, we showed that MindMaze's high-dose, high-intensity therapy, integrated into inpatient rehabilitation, delivers superior functional outcomes in a resource-efficient way,” said Zach Henderson, CEO of MindMaze Therapeutics. “Now, we are demonstrating that this value can extend into the home to address a well-recognized gap in care once patients leave the clinic, in line with the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery. These results, combined with our upcoming MindMotion Lite tablet-based solution, will help make high-quality neurotherapeutics more accessible. Together, these milestones bring us closer to our mission of making neurotherapeutics available at scale.” Study Design and Results The retrospective, multi-site quality improvement program evaluated 177 rehabilitation episodes involving 172 adults with a range of neurological conditions, primarily stroke, across four Vibra Healthcare outpatient sites, without a control group. Participants followed an eight-week home-training program using MindMotion GO, with an optional four-week extension and periodic therapist supervision. Key findings included: Training dose: Patients completed an average of 174 minutes of active training per week, with 84.4% delivered asynchronously. The additional home training increased total motor-training dose by a median factor of 3.0 compared with usual outpatient therapy alone, based on published assumptions for active practice during usual care. Feasibility and engagement: 92.7% successfully completed home setup, while 80.2% achieved the predefined minimum training exposure. Among surveyed participants, 83.8% of satisfaction ratings were positive. Functional outcomes: Statistically significant pre–post improvements were observed in independence (Barthel Index: +10.4 points), balance (Berg Balance Scale: +10.5 points), cognition (SLUMS: +3.4 points) and mobility (Timed Up and Go: −8.8 seconds) among participants with available paired assessments. The full poster, High-Dose, Home-Based Neurorehabilitation Using Gamified Technology: A Multi-Site Quality Improvement Program, is available at mindmazetherapeutics.com/mindmaze-platform/clinical-evidence. About MindMaze Therapeutics MindMaze Therapeutics (SIX: MMTX) is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The company's FDA-listed and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other neurological disorders. With an extensive library of rigorous clinical validation, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine. For more information, visit www.mindmazetherapeutics.com. Media & Investor Contacts Jeremy Meinen, Chief Financial Officer ir@mindmazetherapeutics.com DISCLAIMER This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise. Additional features: File: Press release_MindMaze_Home-Based Rehabilitation Results
BOSTON, Oct. 14, 2026 -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
REDWOOD CITY, Calif., Oct. 14, 2026 -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will release interim clinical data related to its tagmokitug development program evaluating the cytolytic CCR8 antibody with toripalimab in multiple solid tumors on Wednesday, October 28, 2026. Coherus management will host a webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to discuss the data and provide additional context. The company has invited key opinion leaders to join the webcast and provide their clinical perspective.
Gerresheimer among the top 5% of all rated companies Overall score increased to 82 out of 100 points Ranked in the top 1% in sustainable procurement DUSSELDORF, GERMANY - October 14, 2026 - Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, has once again been awarded Gold by the sustainability rating provider EcoVadis. EcoVadis evaluates the management systems of companies worldwide in the categories of environment, labor and human rights, ethics, and sustainable procurement. More than 175,000 companies are evaluated by EcoVadis each year. In the latest rating, Gerresheimer increased its score from 78 (2025) to 82 out of 100 points. This places Gerresheimer among the top 5% of all companies rated by EcoVadis and within the top 2% in its industry. With this rating result, Gerresheimer underscores its progress in consistently implementing its sustainability targets. "With the improved EcoVadis rating and our first voluntary report based on the CSRD, we are making our sustainability performance measurable and transparent for our customers," explains Wolf Lehmann, CFO of Gerresheimer AG. "We remain committed to consistently pursuing our ambitious sustainability targets in the future." Gerresheimer among the top 2% in its industry Since 2011, Gerresheimer has relied on EcoVadis to have its sustainability management independently assessed across four different dimensions. In 2022, Gerresheimer achieved Gold status for the first time with a score of 68 out of 100 points and continued to improve its overall rating in the following years. In 2026, the company once again increased its score to 82 out of 100 points, placing Gerresheimer not only among the top 5% of all companies evaluated by EcoVadis but also within the top 2% in the industry. Gerresheimer performs particularly well in the area of sustainable procurement. Here, Gerresheimer ranks among the top 1% in the industry, underscoring the importance of responsible supply chains for its own sustainability performance. Internationally recognized sustainability rating EcoVadis’ comprehensive Corporate Social Responsibility (CSR) assessment framework is based on internationally recognized standards such as the UN Global Compact, the conventions of the International Labor Organization (ILO), the standards of the Global Reporting Initiative (GRI), the ISO 26000 standard, the CERES Principles, and the UN Guiding Principles on Business and Human Rights. The EcoVadis rating thus covers a wide range of information on companies performance in the areas of the environment, labor and human rights, ethics, and sustainable procurement, while taking industry-specific characteristics into account. Ambitious sustainability targets Gerresheimer has set ambitious goals to achieve measurable progress in the areas of climate protection, the circular economy, responsible supply chains, and social responsibility. With clear performance indicators, transparent reporting, and independent assessments, Gerresheimer ensures that progress is documented comprehensively and can be compared with international benchmarks. For the 2025 financial year, Gerresheimer has, for the first time, voluntarily submitted an audited, non-financial consolidated report based on the Corporate Sustainability Reporting Directive (CSRD). In doing so, the company has significantly advanced the structure of its sustainability reporting. The report is available for download here. In addition, Gerresheimer discloses relevant data annually on the EcoVadis platform and as part of the CDP rating. MSCI, Sustainalytics, and ISS also evaluate the company’s sustainability performance. An overview of Gerresheimer’s external sustainability assessments is available here. About Gerresheimer Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of primary packaging solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes infusion, dropper and syrup bottles, tablet containers, vials, syringes, pens, auto-injectors, inhalers, ampoules, cartridges, on-body devices as well as digital solutions for therapy support. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With 39 production sites in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. The Group generated revenues of around EUR 2.3bn in 2025 and employs over 13,000 people. Gerresheimer AG is listed on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). www.gerresheimer.com Contact Gerresheimer Media Jutta Lorberg Group Senior Director Communication & Marketing T +49 211 6181 264 jutta.lorberg@gerresheimer.com Dersim Korkmaz Manager Corporate Communication T +49 211 6181 296 dersim.korkmaz@gerresheimer.com Investor Relations Guido Pickert Vice President Investor Relations T +49 211 6181 220 gerresheimer.ir@gerresheimer.com
LOS ANGELES, CA - October 14, 2026 - SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced that it submitted its response to a request for additional information from the U.S. Food and Drug Administration (FDA) on Oct. 5, 2026, regarding its 510(k) submission for the SSi Mantra surgical robotic system. The response includes final data from an expanded human clinical and human factors validation study, as well as a bridging study completed in August 2026 at Hospital Internacional de Colombia, a member of the Mayo Clinic Care Network. The submission covers the initial indication of cholecystectomy, or gallbladder removal. The company anticipates that the FDA will complete its review of the response and 510(k) submission in the first quarter of 2027, advancing its efforts to introduce the SSi Mantra system to the U.S. market. To view the full press release, visit https://ibn.fm/A6dJ8 About SS Innovations SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates. About the SSi Mantra The SSi Mantra surgical robotic system is a modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that is intended to provide equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart is designed to provide the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
LOS ANGELES, Oct. 14, 2026 -- The Portnoy Law Firm advises Unicycive Therapeutics, Inc., (“Unicycive” or the "Company") (NASDAQ: UNCY) investors of a class action on behalf of investors that bought securities between December 29, 2025 - June 29, 2026, inclusive (the “Class Period”). Unicycive investors have until November 2, 2026 to file a lead plaintiff motion.
CVS Caremark: Why Transparency Matters in Pharmacy Benefits Mon, 10/19/2026 - 08:15 Body Originally published on CVS Health Company Newsroom Key points 87% of employers say improving cost transparency is one of the biggest opportunities for PBMs CVS Caremark offers tools and solutions that provide greater visibility into pharmacy spending and cost drivers Understanding what drives health care costs has become increasingly important across the health care system. Employers, patients, providers and policymakers are looking for clearer insights into spending, treatment options and strategies that can help make medications and care more affordable and accessible. Key findings from the CVS Caremark-Employee Benefit News study on PBM transparency Recent research conducted by CVS Caremark and Employee Benefit News (EBN) highlights the growing importance of transparency in pharmacy benefits management. In The State of Pharmacy Management survey, 87% of employers said improving cost transparency represents one of the biggest opportunities for pharmacy benefit managers (PBMs), reflecting growing demand for clearer information and greater predictability when managing pharmacy benefits. For many employers, transparency is about making more informed decisions. While most employers report concerns about medication costs, only a minority believe they have significant influence over pharmacy spending. The survey also found that only 24% believe medication costs are fully transparent, highlighting the need for clearer information across the health care system. As health care becomes more complex, employers increasingly want partners that can help them understand not only what they are spending, but what is driving those costs. In the survey, employers identified visibility into pharmacy spending, benefit navigation support and access to affordable medications as key areas where PBMs can provide additional value. How CVS Caremark is bringing greater transparency to pharmacy benefits CVS Caremark is addressing these needs through tools designed to provide more informed benefit decisions. One example is CVS Caremark TrueCost™, which offers a pricing model focused on predictability, accountability, and greater understanding of how pharmacy benefit dollars are spent. Transparency also means giving employers better access to information. CVS Caremark's myPBM platform helps clients monitor pharmacy benefit trends, plan performance and cost drivers, helping identify opportunities for savings and optimize benefit strategies. Transparency can also make health care easier to navigate for patients and providers. When prescribers and pharmacists have access to Real-Time Benefits information and lower-cost alternatives, they can help patients better understand their options before arriving at the pharmacy counter. CVS Caremark has also expanded reporting capabilities that provide clients with greater visibility into drug pricing, rebates, and member costs. CVS CostVantage® and CVS Health's broader approach to transparency Across CVS Health, similar efforts are helping bring greater simplicity to the broader health care system. CVS CostVantage®, for example, is designed to align pharmacy reimbursement more closely with the underlying cost of medications and the services pharmacists provide. CVS Health describes the model as an important step toward greater transparency and sustainability across the pharmacy ecosystem. The CVS Caremark-EBN survey findings point to a broader trend across health care: employers are seeking more than cost management alone. They want clearer information, practical tools and greater confidence that they understand where health care dollars are going and how benefit decisions affect affordability, access and employee health. As health care continues to evolve, transparency will remain an important part of helping employers navigate change. By combining data-driven insights, enhanced reporting, point-of-care cost information and solutions such as TrueCost™, CVS Caremark is helping bring greater transparency to pharmacy benefits and support more informed health care decisions. Featured Image Type of Content Article